fy19 prmrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.
the vision and mission of the prmrp is improve the health, care, and well-being of all military service members, veterans, and beneficiaries by encouraging, identifying, selecting, and managing medical research projects of clear scientific merit and direct relevance to military health
clinical trial award – preproposal due march 14, 2019
· assistant professor level or above (or equivalent)
- preproposal submission is required; application submission is by invitation only.
- supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic area(s) of interest.
- proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.
· investigational new drug or investigational device exemption applications, if needed, should be approved by the food and drug administration before the prmrp application submission deadline.
· a copy of the fda acknowledgement letter and meeting minutes, if applicable, should be submitted with the full application. if the trial will be conducted internationally, a copy of the relevant national regulatory agency approval should be submitted with the full application.
- no maximum funding limit; requested funding should be justifiable and appropriate for the scope of work proposed; budget will be considered during pre-application screening and will be a scored full application criterion.
· maximum period of performance is 4 years
discovery award – letter of intent due march 28, 2019
· postdoctoral fellow or clinical fellow (or equivalent) and above
- supports the exploration of a highly innovative new concept or untested theory in the topic are(s) of interest.
- not intended to support the logical progression of an already established line of questioning.
- clinical trials will not be funded.
· reviewers will be blinded to the identity of the principal investigator (pi), collaborator(s), and their organization(s).
- maximum funding of $200,000 for direct costs (plus indirect costs)
· maximum period of performance is 2 year
focused program award – preproposal due march 14, 2019
· lead pi: full professor level or above (or equivalent)
· project leads: assistant professor level or above (or equivalent)
- preproposal submission is required; application submission is by invitation only.
- supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal in the topic area(s) of interest.
- projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications.
- projects may range from exploratory/hypothesis-developing through small-scale clinical trials that together will address the overarching goal/question.
· research team of highly qualified, multidisciplinary project leaders should be led by a pi with demonstrated success in directing large, focused projects.
- maximum funding of $7.2 million for direct costs (plus indirect costs)
· maximum period of performance is 4 years
investigator-initiated research award – preproposal due march 14, 2019
· assistant professor level or above (or equivalent)
- preproposal submission is required; application submission is by invitation only.
- supports research that will make an original and important contribution to the field of research or patient care in the topic area(s) of interest.
- partnering pi option available.
· clinical trials will not be funded.
- maximum funding of $1.2 million for direct costs (plus indirect costs); $1.5 million for direct costs (plus indirect costs) for applications including a partnering pi option
· maximum period of performance is 3 years
technology/ therapeutic development award – preproposal due march 14, 2019
· assistant professor level or above (or equivalent)
- supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, or quality of life in the topic area(s) of interest.
- product-oriented (e.g., device, drug, clinical guidelines). the product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.
- clinical trials will not be funded.
· preproposal submission is required; application submission is by invitation only.
- maximum funding of $3.0 million for direct costs (plus indirect costs)
· maximum period of performance is 3 years
a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website. the application package containing the required forms for each award mechanism will also be found on grants.gov. a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.
applications must be submitted through the federal government’s single-entry portal, grants.gov. for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org. for more information about the prmrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).
point of contact:
cdmrp help desk
301-682-5507
help@ebrap.org
